Nov 15 (Reuters) - Trillium Therapeutics Inc TRIL.TO -
* Trillium announces private placement
* Trillium Therapeutics - entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares
* Trillium Therapeutics - net proceeds from private placement will be used to continue development of TTI-621 in hematologic cancers and solid tumors
* Trillium Therapeutics Inc - subscription agreements for offering at a price of U.S.$8.50 per share